25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?
Samo za registrovane korisnike
2018
Autori
Đurasinović, Vladislava T.Mihaljević, Biljana
Šipetić-Grujičić, Sandra B.
Ignjatović, Svetlana
Trajković, Goran
Todorović-Balint, Milena R.
Antić, Darko
Bila, Jelena S.
Anđelić, Bosko M.
Jelicić, Jelena J.
Vuković, Vojin M.
Nikolić, Aleksandra M.
Klek, Stanislaw
Članak u časopisu (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
Introduction Vitamin D has a role in cellular differentiation, proliferation, apoptosis, and angiogenesis and therefore is studied as a prognostic factor in cancer. The aim of our study was to assess the prevalence and significance of 25(OH)D deficiency in patients with lymphoid malignancies. Methodology Between January 2014 and June 2016 at the Clinic for Hematology, Clinical Center of Serbia, Belgrade, the pretreatment serum level of 25(OH)D was determined in 133 (62 women/71 men, median age 58 (18-84) years) previously untreated patients with lymphoid malignancy using a chemiluminescent immunoassay. From their medical records, we noted the age, clinical stage, Eastern Cooperative Oncology Group Performance Scale (ECOG PS), nutritional status using the Nutritional Risk Score 2002 (NRS2002), the time of year, comorbidity index, progression, and progression-free survival (PFS) for a median of 20 (1-32) months. The optimal cutoff point for prediction of outcome was determined using the ...Maximally Selected Rank Statistics. Results There were 37 (27.8%) patients with the severe 25(OH)D deficiency lt = 25 nmol/l, 80 (60.2%) with 25(OH)D deficiency 25-50 nmol/l, and 16 (12%) with 25(OH)D insufficiency 50-75 nmol/l. None of the patients had the desired normal level. There were significant differences between groups in regard to ECOG PS, NRS2002, type of lymphoma, and progression. The severely 25(OH)D-deficient patients had a shorter mean time until progression (P = 0.018). Cox regression analysis showed that 25(OH)D lt 19.6 nmol/l remained the only significant parameter for PFS (HR = 2.921; 95% CI 1.307-6.529). Conclusion The prevalence of 25(OH)D deficiency in the analyzed group of patients with lymphoid malignancies is high and greater in malnourished individuals. Patients with pretreatment serum 25(OH)D lt 19.6 nmol/l had a significantly shorter PFS.
Ključne reči:
25(OH)D level / LymphomaIzvor:
Synthetic Communications, 2018, 26, 8, 2825-2832Izdavač:
- Springer, New York
Finansiranje / projekti:
- Biomarkeri oštećenja i disfunkcije organa (RS-MESTD-Basic Research (BR or ON)-175036)
DOI: 10.1007/s00520-018-4101-9
ISSN: 0941-4355
PubMed: 29511954
WoS: 000436242800037
Scopus: 2-s2.0-85049436913
Institucija/grupa
PharmacyTY - JOUR AU - Đurasinović, Vladislava T. AU - Mihaljević, Biljana AU - Šipetić-Grujičić, Sandra B. AU - Ignjatović, Svetlana AU - Trajković, Goran AU - Todorović-Balint, Milena R. AU - Antić, Darko AU - Bila, Jelena S. AU - Anđelić, Bosko M. AU - Jelicić, Jelena J. AU - Vuković, Vojin M. AU - Nikolić, Aleksandra M. AU - Klek, Stanislaw PY - 2018 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3236 AB - Introduction Vitamin D has a role in cellular differentiation, proliferation, apoptosis, and angiogenesis and therefore is studied as a prognostic factor in cancer. The aim of our study was to assess the prevalence and significance of 25(OH)D deficiency in patients with lymphoid malignancies. Methodology Between January 2014 and June 2016 at the Clinic for Hematology, Clinical Center of Serbia, Belgrade, the pretreatment serum level of 25(OH)D was determined in 133 (62 women/71 men, median age 58 (18-84) years) previously untreated patients with lymphoid malignancy using a chemiluminescent immunoassay. From their medical records, we noted the age, clinical stage, Eastern Cooperative Oncology Group Performance Scale (ECOG PS), nutritional status using the Nutritional Risk Score 2002 (NRS2002), the time of year, comorbidity index, progression, and progression-free survival (PFS) for a median of 20 (1-32) months. The optimal cutoff point for prediction of outcome was determined using the Maximally Selected Rank Statistics. Results There were 37 (27.8%) patients with the severe 25(OH)D deficiency lt = 25 nmol/l, 80 (60.2%) with 25(OH)D deficiency 25-50 nmol/l, and 16 (12%) with 25(OH)D insufficiency 50-75 nmol/l. None of the patients had the desired normal level. There were significant differences between groups in regard to ECOG PS, NRS2002, type of lymphoma, and progression. The severely 25(OH)D-deficient patients had a shorter mean time until progression (P = 0.018). Cox regression analysis showed that 25(OH)D lt 19.6 nmol/l remained the only significant parameter for PFS (HR = 2.921; 95% CI 1.307-6.529). Conclusion The prevalence of 25(OH)D deficiency in the analyzed group of patients with lymphoid malignancies is high and greater in malnourished individuals. Patients with pretreatment serum 25(OH)D lt 19.6 nmol/l had a significantly shorter PFS. PB - Springer, New York T2 - Synthetic Communications T1 - 25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it? VL - 26 IS - 8 SP - 2825 EP - 2832 DO - 10.1007/s00520-018-4101-9 ER -
@article{ author = "Đurasinović, Vladislava T. and Mihaljević, Biljana and Šipetić-Grujičić, Sandra B. and Ignjatović, Svetlana and Trajković, Goran and Todorović-Balint, Milena R. and Antić, Darko and Bila, Jelena S. and Anđelić, Bosko M. and Jelicić, Jelena J. and Vuković, Vojin M. and Nikolić, Aleksandra M. and Klek, Stanislaw", year = "2018", abstract = "Introduction Vitamin D has a role in cellular differentiation, proliferation, apoptosis, and angiogenesis and therefore is studied as a prognostic factor in cancer. The aim of our study was to assess the prevalence and significance of 25(OH)D deficiency in patients with lymphoid malignancies. Methodology Between January 2014 and June 2016 at the Clinic for Hematology, Clinical Center of Serbia, Belgrade, the pretreatment serum level of 25(OH)D was determined in 133 (62 women/71 men, median age 58 (18-84) years) previously untreated patients with lymphoid malignancy using a chemiluminescent immunoassay. From their medical records, we noted the age, clinical stage, Eastern Cooperative Oncology Group Performance Scale (ECOG PS), nutritional status using the Nutritional Risk Score 2002 (NRS2002), the time of year, comorbidity index, progression, and progression-free survival (PFS) for a median of 20 (1-32) months. The optimal cutoff point for prediction of outcome was determined using the Maximally Selected Rank Statistics. Results There were 37 (27.8%) patients with the severe 25(OH)D deficiency lt = 25 nmol/l, 80 (60.2%) with 25(OH)D deficiency 25-50 nmol/l, and 16 (12%) with 25(OH)D insufficiency 50-75 nmol/l. None of the patients had the desired normal level. There were significant differences between groups in regard to ECOG PS, NRS2002, type of lymphoma, and progression. The severely 25(OH)D-deficient patients had a shorter mean time until progression (P = 0.018). Cox regression analysis showed that 25(OH)D lt 19.6 nmol/l remained the only significant parameter for PFS (HR = 2.921; 95% CI 1.307-6.529). Conclusion The prevalence of 25(OH)D deficiency in the analyzed group of patients with lymphoid malignancies is high and greater in malnourished individuals. Patients with pretreatment serum 25(OH)D lt 19.6 nmol/l had a significantly shorter PFS.", publisher = "Springer, New York", journal = "Synthetic Communications", title = "25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?", volume = "26", number = "8", pages = "2825-2832", doi = "10.1007/s00520-018-4101-9" }
Đurasinović, V. T., Mihaljević, B., Šipetić-Grujičić, S. B., Ignjatović, S., Trajković, G., Todorović-Balint, M. R., Antić, D., Bila, J. S., Anđelić, B. M., Jelicić, J. J., Vuković, V. M., Nikolić, A. M.,& Klek, S.. (2018). 25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?. in Synthetic Communications Springer, New York., 26(8), 2825-2832. https://doi.org/10.1007/s00520-018-4101-9
Đurasinović VT, Mihaljević B, Šipetić-Grujičić SB, Ignjatović S, Trajković G, Todorović-Balint MR, Antić D, Bila JS, Anđelić BM, Jelicić JJ, Vuković VM, Nikolić AM, Klek S. 25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?. in Synthetic Communications. 2018;26(8):2825-2832. doi:10.1007/s00520-018-4101-9 .
Đurasinović, Vladislava T., Mihaljević, Biljana, Šipetić-Grujičić, Sandra B., Ignjatović, Svetlana, Trajković, Goran, Todorović-Balint, Milena R., Antić, Darko, Bila, Jelena S., Anđelić, Bosko M., Jelicić, Jelena J., Vuković, Vojin M., Nikolić, Aleksandra M., Klek, Stanislaw, "25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?" in Synthetic Communications, 26, no. 8 (2018):2825-2832, https://doi.org/10.1007/s00520-018-4101-9 . .